Seborrheic Dermatitis Pathophysiology and Management

Introduction to Seborrheic Dermatitis

• The American Academy of Dermatology suggests that seborrheic dermatitis is primarily a localized inflammatory response to fungal metabolites in sebaceous-rich areas, not a manifestation of internal dysbiosis 1, 2

Skin Microbiome Alterations

• Seborrheic dermatitis involves specific alterations in the skin microbiome, including decreased fungal diversity with increased Malassezia species that metabolize sebum triglycerides into irritating free fatty acids, triggering local inflammation 1

Clinical Associations and Implications

• The condition is more pronounced in HIV infection, Parkinson's disease, and Down syndrome, suggesting immune and neurological factors rather than gut dysbiosis 1
• Seborrheic dermatitis frequently coexists with rosacea (51%) and dry eye (25-40%), pointing to immune dysfunction and sebaceous gland regulation rather than intestinal microbiome issues 1, 2

Treatment and Management

• The American Academy of Dermatology recommends first-line treatment with topical antifungals targeting Malassezia (ketoconazole, ciclopirox) 2
• Adjunctive treatment includes short-term low-potency topical corticosteroids for inflammation 1, 2
• Maintenance therapy involves ongoing antifungal therapy due to the chronic relapsing nature of the condition 1, 2

Epidemiology and Disease Characteristics

• 95% of patients with seborrheic blepharitis have seborrheic dermatitis elsewhere, confirming this is a widespread skin condition affecting multiple sebaceous-rich sites simultaneously, not a gut-mediated systemic disease 1, 2